We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid AST Platform Provides Targeted Therapeutic Results Days Faster Than Current Standard of Care

By LabMedica International staff writers
Posted on 08 Mar 2024

Bacteria are outpacing scientific advancements, leading to a worrying increase in antibiotic resistance, a situation the World Health Organization has identified as an emerging global health crisis. The key to countering this trend lies in achieving quicker diagnostic results, comprehensive susceptibility testing across various sample types, and the ability to test against a broad range of commercially relevant antibiotics simultaneously. Now, a rapid antibiotic susceptibility testing (AST) system can provide targeted therapeutic results days faster than the current standard of care.

Selux Diagnostics (Boston, MA, USA) has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary Positive Blood Culture (PBC) Separator. The addition of positive blood culture sample type expands the Selux Next Generation Phenotyping (NGP) System, making this the only FDA-cleared, single-platform technology to deliver rapid AST results for both positive blood culture and isolated colonies.


Image: The Selux PBC Separator with Selux AST System has received FDA 510(k) clearance (Photo courtesy of Selux Diagnostics)
Image: The Selux PBC Separator with Selux AST System has received FDA 510(k) clearance (Photo courtesy of Selux Diagnostics)

The Selux PBC Separator streamlines the process for laboratories by enabling direct testing from positive blood culture samples, eliminating the need to subculture. This automated sample preparation for susceptibility testing enhances efficiency significantly. The recent FDA clearance allows the determination of bacterial susceptibility to 17 distinct antibiotic agents included in the Selux Gram Negative Panel. Previously awarded the FDA Breakthrough Designation, the Selux PBC Separator is recognized for its potential to meet the urgent need for conducting AST directly from positive blood culture samples and other sterile body fluids.

"This third 510(k) clearance for Selux marks a significant advancement in infectious disease care,” said Steve Lufkin, CEO of Selux Diagnostics. “The Selux NGP System is the only AST platform able to deliver rapid AST results direct from positive blood culture and isolated colonies. We extend our gratitude to our employees, partners, and advisors whose contributions were instrumental in achieving this breakthrough designated accomplishment."

Related Links:
Selux Diagnostics


Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Automated Blood Typing System
IH-500 NEXT
New
FLU/RSV Test
Humasis FLU/RSV Combo
New
Thyroxine ELISA
T4 ELISA

Latest Microbiology News

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Innovative Diagnostic Approach for Bacterial Infections to Enable Faster and Effective Treatment